<p>在澳大利亞市場面臨貿易放緩和投資者謹慎的背景下，識別具有顯著內部持股的成長型公司可以為潛在投資機會提供有價值的見解。在這種信心受到地緣政治不確定性影響的環境中，強大的內部承諾的股票可能表明對公司長期前景的更高信任度。</p>
<h3>澳大利亞內部持股高的十大成長型公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股</strong></td>
<td><strong>盈利增長</strong></td>
</tr>
<tr>
<td>Alfabs Australia (ASX:AAL)</td>
<td>10.8%</td>
<td>41.3%</td>
</tr>
<tr>
<td>Fenix Resources (ASX:FEX)</td>
<td>21.1%</td>
<td>47.8%</td>
</tr>
<tr>
<td>Cyclopharm (ASX:CYC)</td>
<td>11.3%</td>
<td>97.8%</td>
</tr>
<tr>
<td>Acrux (ASX:ACR)</td>
<td>15.5%</td>
<td>106.9%</td>
</tr>
<tr>
<td>Newfield Resources (ASX:NWF)</td>
<td>31.5%</td>
<td>72.1%</td>
</tr>
<tr>
<td>Echo IQ (ASX:EIQ)</td>
<td>19.8%</td>
<td>111.1%</td>
</tr>
<tr>
<td>Titomic (ASX:TTT)</td>
<td>11.2%</td>
<td>77.2%</td>
</tr>
<tr>
<td>Plenti Group (ASX:PLT)</td>
<td>12.7%</td>
<td>85%</td>
</tr>
<tr>
<td>Image Resources (ASX:IMA)</td>
<td>16.1%</td>
<td>127.3%</td>
</tr>
<tr>
<td>BETR Entertainment (ASX:BBT)</td>
<td>38.6%</td>
<td>77.5%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們內部持股高的快速成長 ASX 公司篩選器中的 93 只股票的完整列表。</p>
<p>我們將查看篩選工具中一些最佳選擇。</p>
<h2>Aurelia Metals (ASX:AMI)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Aurelia Metals Limited 是一家澳大利亞公司，專注於礦產資源的勘探和生產，市值為 4.5699 億澳元。</p>
<p><strong>運營：</strong> 公司的收入主要來自於 Peak 礦（2.4513 億澳元）、Dargues 礦（7390 萬澳元）和 Hera 礦（598 萬澳元）的運營。</p>
<p><strong>內部持股：</strong> 23.9%</p>
<p>Aurelia Metals 作為一傢俱有實質內部持股的成長型公司展現出良好前景，最近幾個月內部人士的顯著買入證明了這一點。公司已恢復盈利，報告截至 2024 年 12 月的半年淨收入為 1795 萬澳元，而之前則出現虧損。儘管黃金和白銀的產量下降，但銅的產量顯著增加。分析師預測年盈利增長將達到 23.6%，超過澳大利亞市場預期的 11.7% 的增長率。</p>
<ul>
<li>解鎖我們對 Aurelia Metals 股票分析的全面見解，詳見本成長報告。</li>
<li>我們編制的估值報告表明，Aurelia Metals 當前的價格可能相對適中。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/46a37689-ee1f-4def-96e3-c3eb839fa866/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/46a37689-ee1f-4def-96e3-c3eb839fa866/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 4 月的 ASX:AMI 盈利和收入增長</p>
<h2>Clarity Pharmaceuticals (ASX:CU6)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Clarity Pharmaceuticals Ltd 是一家臨牀階段的放射藥物公司，專注於在澳大利亞和美國研發放射藥物產品，市值為 5.3987 億澳元。</p>
<p><strong>運營：</strong> 公司的收入部分來自放射藥物開發，產生 1078 萬澳元的收入。</p>
<p><strong>內部持股：</strong> 17.8%</p>
<p>Clarity Pharmaceuticals 展現出強大的增長潛力，得益於其創新的 Cu-SAR-bisPSMA 前列腺癌治療平台。最近的試驗進展顯示出良好的療效和安全性，重度預處理參與者的 PSA 顯著降低。FDA 的快速通道認證支持加速開發。儘管截至 2024 年 12 月的半年淨虧損為 2358 萬澳元，但收入從 652 萬澳元增長至 1094 萬澳元，預測顯示收入增長迅速，超過市場平均水平。</p>
<ul>
<li>在我們的盈利增長報告中更深入地瞭解 Clarity Pharmaceuticals 的潛力。</li>
<li>我們的估值報告顯示 Clarity Pharmaceuticals 可能被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4f738db8-37ac-4398-b17d-c71a9e354b96/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4f738db8-37ac-4398-b17d-c71a9e354b96/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 4 月的 ASX:CU6 盈利和收入增長</p>
<h2>IperionX (ASX:IPX)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> IperionX Limited 專注於在美國的礦產資源勘探和開發，市值約為 9 億澳元。</p>
<p><strong>運營：</strong> 提供的文本中未具體説明 IperionX Limited 的收入部分。</p>
<p><strong>內部持股：</strong> 19.2%</p>
<p>IperionX 憑藉其在田納西州的 Titan 關鍵礦產項目和戰略性美國合作伙伴關係，正處於顯著增長的有利位置，包括獲得 4710 萬美元的政府獎勵以增強鈦供應鏈。儘管最近股東稀釋和截至 2024 年 12 月的半年淨虧損為 1624 萬美元，IperionX 的收入預計將迅速增長，超過市場平均水平，預計在三年內實現盈利，得益於創新技術和實質內部持股。</p>
<ul>
<li>點擊這裏發現 IperionX 的細微差別，查看我們的詳細分析未來增長報告。</li>
<li>我們的全面估值報告提出 IperionX 的定價可能高於其財務狀況所能證明的水平。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4e8dfcb7-c0e0-4531-b20e-c5e49bcf6fb0/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4e8dfcb7-c0e0-4531-b20e-c5e49bcf6fb0/chart/ownership-breakdown"/></p>
<p>截至 2025 年 4 月的 ASX:IPX 持股結構</p>
<h2>接下來該怎麼辦？</h2>
<ul>
<li>點擊進入，開始探索其餘 90 家內部持股高的快速成長 ASX 公司。</li>
<li>考慮其他策略？這項技術可能取代計算機：發現 22 只股票正在努力使量子計算成為現實。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章不應被視為財務建議。</strong> 它不構成買賣任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
<p>如果您想交易 IperionX，請在專業人士信賴的最低成本平台 Interactive Brokers 開設賬户。</p>
<p>IBKR 在 200 多個國家和地區擁有客户，並可訪問 160 個市場，讓您可以通過一個集成賬户交易股票、期權、期貨、外匯、債券和基金。</p>
<p>享受無隱藏費用，無賬户最低要求，外匯轉換率低至 0.03%，遠低於大多數經紀商提供的費用。</p>
<p>贊助內容</p>

<p>澳大利亞市場目前因全球緊張局勢面臨貿易放緩和投資者謹慎。識別具有顯著內部持股的成長型公司可以提供投資洞察。值得注意的公司包括 Aurelia Metals（23.9% 內部持股，23.6% 盈利增長）、Clarity Pharmaceuticals（17.8% 內部持股，快速收入增長）和 IperionX（19.2% 內部持股，預計三年內實現盈利）。儘管近期面臨挑戰，這些公司仍顯示出潛力，內部持股表明對其長期前景的信心</p>

<p>As the Australian market navigates a period of slower trade and investor caution amid ongoing global tensions, identifying growth companies with significant insider ownership can offer valuable insights into potential investment opportunities. In this environment, where confidence is tempered by geopolitical uncertainties, stocks with strong insider commitment may signal a higher level of trust in the company's long-term prospects.</p>
<div class="lb-trans"><p>在澳大利亞市場面臨貿易放緩和投資者謹慎的背景下，識別具有顯著內部持股的成長型公司可以為潛在投資機會提供有價值的見解。在這種信心受到地緣政治不確定性影響的環境中，強大的內部承諾的股票可能表明對公司長期前景的更高信任度。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In Australia</h3>
<div class="lb-trans"><h3>澳大利亞內部持股高的十大成長型公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Alfabs Australia (ASX:AAL)</td>
<td>10.8%</td>
<td>41.3%</td>
</tr>
<tr>
<td>Fenix Resources (ASX:FEX)</td>
<td>21.1%</td>
<td>47.8%</td>
</tr>
<tr>
<td>Cyclopharm (ASX:CYC)</td>
<td>11.3%</td>
<td>97.8%</td>
</tr>
<tr>
<td>Acrux (ASX:ACR)</td>
<td>15.5%</td>
<td>106.9%</td>
</tr>
<tr>
<td>Newfield Resources (ASX:NWF)</td>
<td>31.5%</td>
<td>72.1%</td>
</tr>
<tr>
<td>Echo IQ (ASX:EIQ)</td>
<td>19.8%</td>
<td>111.1%</td>
</tr>
<tr>
<td>Titomic (ASX:TTT)</td>
<td>11.2%</td>
<td>77.2%</td>
</tr>
<tr>
<td>Plenti Group (ASX:PLT)</td>
<td>12.7%</td>
<td>85%</td>
</tr>
<tr>
<td>Image Resources (ASX:IMA)</td>
<td>16.1%</td>
<td>127.3%</td>
</tr>
<tr>
<td>BETR Entertainment (ASX:BBT)</td>
<td>38.6%</td>
<td>77.5%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股</strong></td>
<td><strong>盈利增長</strong></td>
</tr>
<tr>
<td>Alfabs Australia (ASX:AAL)</td>
<td>10.8%</td>
<td>41.3%</td>
</tr>
<tr>
<td>Fenix Resources (ASX:FEX)</td>
<td>21.1%</td>
<td>47.8%</td>
</tr>
<tr>
<td>Cyclopharm (ASX:CYC)</td>
<td>11.3%</td>
<td>97.8%</td>
</tr>
<tr>
<td>Acrux (ASX:ACR)</td>
<td>15.5%</td>
<td>106.9%</td>
</tr>
<tr>
<td>Newfield Resources (ASX:NWF)</td>
<td>31.5%</td>
<td>72.1%</td>
</tr>
<tr>
<td>Echo IQ (ASX:EIQ)</td>
<td>19.8%</td>
<td>111.1%</td>
</tr>
<tr>
<td>Titomic (ASX:TTT)</td>
<td>11.2%</td>
<td>77.2%</td>
</tr>
<tr>
<td>Plenti Group (ASX:PLT)</td>
<td>12.7%</td>
<td>85%</td>
</tr>
<tr>
<td>Image Resources (ASX:IMA)</td>
<td>16.1%</td>
<td>127.3%</td>
</tr>
<tr>
<td>BETR Entertainment (ASX:BBT)</td>
<td>38.6%</td>
<td>77.5%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 93 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們內部持股高的快速成長 ASX 公司篩選器中的 93 只股票的完整列表。</p>
</div><p>We're going to check out a few of the best picks from our screener tool.</p>
<div class="lb-trans"><p>我們將查看篩選工具中一些最佳選擇。</p>
</div><h2>Aurelia Metals (ASX:AMI)</h2>
<div class="lb-trans"><h2>Aurelia Metals (ASX:AMI)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Aurelia Metals Limited is an Australian company involved in the exploration and production of mineral properties, with a market capitalization of A$456.99 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Aurelia Metals Limited 是一家澳大利亞公司，專注於礦產資源的勘探和生產，市值為 4.5699 億澳元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its operations at the Peak Mine (A$245.13 million), Dargues Mine (A$73.90 million), and Hera Mine (A$5.98 million).</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自於 Peak 礦（2.4513 億澳元）、Dargues 礦（7390 萬澳元）和 Hera 礦（598 萬澳元）的運營。</p>
</div><p><strong>Insider Ownership:</strong> 23.9%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 23.9%</p>
</div><p>Aurelia Metals shows promise as a growth company with substantial insider ownership, evidenced by significant insider buying in recent months. The company has returned to profitability, reporting A$17.95 million net income for the half-year ending December 2024 compared to a loss previously. While gold and silver production declined, copper output increased significantly. Analysts forecast robust annual earnings growth of 23.6%, outpacing the broader Australian market's expected growth rate of 11.7%.</p>
<div class="lb-trans"><p>Aurelia Metals 作為一傢俱有實質內部持股的成長型公司展現出良好前景，最近幾個月內部人士的顯著買入證明了這一點。公司已恢復盈利，報告截至 2024 年 12 月的半年淨收入為 1795 萬澳元，而之前則出現虧損。儘管黃金和白銀的產量下降，但銅的產量顯著增加。分析師預測年盈利增長將達到 23.6%，超過澳大利亞市場預期的 11.7% 的增長率。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Aurelia Metals stock in this growth report.</li>
<li>The valuation report we've compiled suggests that Aurelia Metals' current price could be quite moderate.</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖我們對 Aurelia Metals 股票分析的全面見解，詳見本成長報告。</li>
<li>我們編制的估值報告表明，Aurelia Metals 當前的價格可能相對適中。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/46a37689-ee1f-4def-96e3-c3eb839fa866/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/46a37689-ee1f-4def-96e3-c3eb839fa866/chart/earnings-and-revenue-growth"/></p>
<p>ASX:AMI Earnings and Revenue Growth as at Apr 2025</p>
<div class="lb-trans"><p>截至 2025 年 4 月的 ASX:AMI 盈利和收入增長</p>
</div><h2>Clarity Pharmaceuticals (ASX:CU6)</h2>
<div class="lb-trans"><h2>Clarity Pharmaceuticals (ASX:CU6)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Clarity Pharmaceuticals Ltd is a clinical stage radiopharmaceutical company focused on research and development of radiopharmaceutical products in Australia and the United States, with a market cap of A$539.87 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Clarity Pharmaceuticals Ltd 是一家臨牀階段的放射藥物公司，專注於在澳大利亞和美國研發放射藥物產品，市值為 5.3987 億澳元。</p>
</div><p><strong>Operations:</strong> The company's revenue segment consists of Radiopharmaceutical Development, generating A$10.78 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入部分來自放射藥物開發，產生 1078 萬澳元的收入。</p>
</div><p><strong>Insider Ownership:</strong> 17.8%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 17.8%</p>
</div><p>Clarity Pharmaceuticals demonstrates strong growth potential, driven by its innovative Cu-SAR-bisPSMA platform for prostate cancer treatment. Recent trial advancements show promising efficacy and safety, with significant PSA reductions in heavily pre-treated participants. The FDA's Fast Track Designation supports accelerated development. Despite a net loss of A$23.58 million for the half-year ending December 2024, revenue grew to A$10.94 million from A$6.52 million year-over-year, with forecasts indicating rapid revenue growth exceeding market averages.</p>
<div class="lb-trans"><p>Clarity Pharmaceuticals 展現出強大的增長潛力，得益於其創新的 Cu-SAR-bisPSMA 前列腺癌治療平台。最近的試驗進展顯示出良好的療效和安全性，重度預處理參與者的 PSA 顯著降低。FDA 的快速通道認證支持加速開發。儘管截至 2024 年 12 月的半年淨虧損為 2358 萬澳元，但收入從 652 萬澳元增長至 1094 萬澳元，預測顯示收入增長迅速，超過市場平均水平。</p>
</div><ul>
<li>Take a closer look at Clarity Pharmaceuticals' potential here in our earnings growth report.</li>
<li>Our valuation report here indicates Clarity Pharmaceuticals may be overvalued.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的盈利增長報告中更深入地瞭解 Clarity Pharmaceuticals 的潛力。</li>
<li>我們的估值報告顯示 Clarity Pharmaceuticals 可能被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4f738db8-37ac-4398-b17d-c71a9e354b96/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/4f738db8-37ac-4398-b17d-c71a9e354b96/chart/earnings-and-revenue-growth"/></p>
<p>ASX:CU6 Earnings and Revenue Growth as at Apr 2025</p>
<div class="lb-trans"><p>截至 2025 年 4 月的 ASX:CU6 盈利和收入增長</p>
</div><h2>IperionX (ASX:IPX)</h2>
<div class="lb-trans"><h2>IperionX (ASX:IPX)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> IperionX Limited is involved in the exploration and development of mineral properties in the United States, with a market capitalization of approximately A$900.03 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> IperionX Limited 專注於在美國的礦產資源勘探和開發，市值約為 9 億澳元。</p>
</div><p><strong>Operations:</strong> IperionX Limited's revenue segments are not specified in the provided text.</p>
<div class="lb-trans"><p><strong>運營：</strong> 提供的文本中未具體説明 IperionX Limited 的收入部分。</p>
</div><p><strong>Insider Ownership:</strong> 19.2%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 19.2%</p>
</div><p>IperionX is poised for significant growth, driven by its Titan Critical Minerals Project in Tennessee and strategic U.S. partnerships, including a USD 47.1 million government award to enhance the titanium supply chain. Despite recent shareholder dilution and a net loss of USD 16.24 million for the half-year ending December 2024, IperionX's revenue is forecast to grow rapidly, outpacing market averages with expected profitability within three years, supported by innovative technologies and substantial insider ownership.</p>
<div class="lb-trans"><p>IperionX 憑藉其在田納西州的 Titan 關鍵礦產項目和戰略性美國合作伙伴關係，正處於顯著增長的有利位置，包括獲得 4710 萬美元的政府獎勵以增強鈦供應鏈。儘管最近股東稀釋和截至 2024 年 12 月的半年淨虧損為 1624 萬美元，IperionX 的收入預計將迅速增長，超過市場平均水平，預計在三年內實現盈利，得益於創新技術和實質內部持股。</p>
</div><ul>
<li>Click here to discover the nuances of IperionX with our detailed analytical future growth report.</li>
<li>Our comprehensive valuation report raises the possibility that IperionX is priced higher than what may be justified by its financials.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏發現 IperionX 的細微差別，查看我們的詳細分析未來增長報告。</li>
<li>我們的全面估值報告提出 IperionX 的定價可能高於其財務狀況所能證明的水平。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4e8dfcb7-c0e0-4531-b20e-c5e49bcf6fb0/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/4e8dfcb7-c0e0-4531-b20e-c5e49bcf6fb0/chart/ownership-breakdown"/></p>
<p>ASX:IPX Ownership Breakdown as at Apr 2025</p>
<div class="lb-trans"><p>截至 2025 年 4 月的 ASX:IPX 持股結構</p>
</div><h2>Where To Now?</h2>
<div class="lb-trans"><h2>接下來該怎麼辦？</h2>
</div><ul>
<li>Click through to start exploring the rest of the 90 Fast Growing ASX Companies With High Insider Ownership now.</li>
<li>Contemplating Other Strategies? This technology could replace computers: discover the 22 stocks are working to make quantum computing a reality.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊進入，開始探索其餘 90 家內部持股高的快速成長 ASX 公司。</li>
<li>考慮其他策略？這項技術可能取代計算機：發現 22 只股票正在努力使量子計算成為現實。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章不應被視為財務建議。</strong> 它不構成買賣任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
</div><p>If you're looking to trade IperionX, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.</p>
<div class="lb-trans"><p>如果您想交易 IperionX，請在專業人士信賴的最低成本平台 Interactive Brokers 開設賬户。</p>
</div><p>With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.</p>
<div class="lb-trans"><p>IBKR 在 200 多個國家和地區擁有客户，並可訪問 160 個市場，讓您可以通過一個集成賬户交易股票、期權、期貨、外匯、債券和基金。</p>
</div><p>Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.</p>
<div class="lb-trans"><p>享受無隱藏費用，無賬户最低要求，外匯轉換率低至 0.03%，遠低於大多數經紀商提供的費用。</p>
</div><p>Sponsored Content</p>
<div class="lb-trans"><p>贊助內容</p>
</div>

3 家 ASX 增長型公司，內部持股比例最高可達 23%